The swine vaccines market size is estimated to be USD 1,698.5 million in 2022 and is expected to witness a CAGR of 5.87% during the forecast period 2023-2033.  Increasing introduction of new vaccines by government and pharmaceutical industries and surge in launch of advanced vaccine technologies and solutions are projected to drive the market growth in near future. Furthermore, escalating swine disease outbreaks and zoonoses, together with the widespread use of antibiotic-free disease prevention techniques are other factors supporting the market growth. However, rising storage price of vaccines are predicted to limit market growth are expected to restrain the market growth.

Increasing introduction of new vaccines by government and pharmaceutical industries is expected to propel the market growth during the projected period. To combat this severe swine health issue, governmental agencies and the pharmaceutical industry are constantly introducing new vaccines. For instance, in June 2022 Vietnam declared that it had created the ASF vaccine, which was intended to be distributed throughout the nation’s swine farms.

Surge in launch of advanced vaccine technologies and solutions is predicted to spur the market growth during the forecast period. Companies are launching a range of cutting-edge vaccine technologies and solutions, which is also boosting market expansion. For instance, Boehringer Ingelheim received approval from the EMA in October 2019 for ReprocycParvoFLEX, the first subunit porcine parvovirus vaccine to guard against transplacental infection in swine fetuses.

Segmentation

By Product

The market is categorized into inactivated vaccines, DNA vaccines, attenuated live vaccines, recombinant vaccines, subunit vaccines. In 2022, the inactivated vaccines segment accounted for the highest revenue share due to its advantages over live-attenuated vaccines in terms of accessibility, affordability, and stability. As they inhibit pathogens from replicating, they reduce the risk of virulence reversal following immunization. Additionally, it provides faster cell-mediated immune responses and better immunizations for swine. With the use of adjuvants as specific kinds of oils or aluminium hydroxide, the immunity brought on by inactivated vaccines can be further strengthened. The recombinant vaccine segment is anticipated to expand at the fastest rate over the projection period. It is expected that these vaccines will help in the vaccination against a variety of viral strains due to the ability of recombinants to carry several gene inserts.

By Type

The market is segmented into classical swine fever, foot & mouth disease, pseudorabies, swine influenza, porcine parvovirus, PEDV, M. Hyo, PRRS, porcine circovirus type 2, actinobacillus pleuropneumonia, and others. In the global market, the PRRS (Porcine Reproductive and Respiratory Syndrome) segment accounted for the largest revenue share in 2022 owing to its widespread occurrence in major swine-raising nations. In the US and a few Asian nations, this disease is both endemic and epidemic. In China, which has the world’s largest swine industry, the disease has been considered an epidemic for more than 20 years. The viral genome exhibits significant variability as a result of RNA transcription’s intrinsic errors. It is expected that the other swine disease types, including ileitis, Glasser’s disease, and newborn diarrhoea, will grow at the fastest rate over the projected period. The growth is attributed to its high frequency in swine herds in developing nations.

Regional Markets

In 2022, North America region accounted for the highest revenue in the swine vaccines market and is expected to maintain its dominance during the forecast period. This is attributed to leading swine producers including China, a sizable meat-eating population, and a widespread need for vaccines to stop the present growing disease outbreaks across Asian swine herds. A total of 462.6 million pigs lived in Asia in 2021, with China having the biggest number of pigs at about 347 million. Additionally, it was estimated that 43,843 thousand tonnes of pork would be consumed in China in 2021. The swine vaccines market in other regions, such as Latin America, North America, and Europe, is anticipated to experience considerable growth throughout the forecast period due to the growing swine population and widespread use of biosecurity measures together with routine vaccination.

Competitor Insights

Some of the key players operating in the swine vaccines market are KM Biologics, Zoetis, HIPRA, Merck & Co., Inc, Elanco, BiogénesisBagó, Phibro Animal Health, Ceva, Indian Immunologicals Ltd., BoehringerIngelheim GmbH, and Virbac.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, in February 2021 Algenex SL and Virbac announced that they had signed into a global licencing agreement for the development and marketing of a CrisBio-based vaccine in a key swine indication.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product and type from 2022 to 2033.

Report Scope:

Segmentation: Swine Vaccines Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Inactivated Vaccines
• DNA Vaccines
• Attenuated Live Vaccines
• Recombinant Vaccines
• Subunit Vaccines

Type (Revenue, USD Million), 2022 – 2033

• Classical Swine Fever
• Foot & Mouth Disease
• Pseudorabies
• Swine Influenza
• Porcine Parvovirus
• PEDV
• Hyo
• PRRS
• Porcine Circovirus Type 2
• Actinobacillus Pleuropneumonia
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA